Does the media favor GLUE or CCCC?

In the previous week, Monte Rosa Therapeutics had 7 more articles in the media than C4 Therapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Monte Rosa Therapeutics' score of 0.08 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or CCCC?

In the previous week, Nuvation Bio had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Nuvation Bio and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Nuvation Bio's score of 0.63 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CCCC or ATAI?

C4 Therapeutics has higher revenue and earnings than Atai Beckley. C4 Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio C4 Therapeutics $35.95M 13.23 -$104.99M -$1.19 N/A Atai Beckley $4.09M 467.19 -$660.05M -$2.23 N/A

Does the media refer more to CCCC or ATAI?

In the previous week, C4 Therapeutics and C4 Therapeutics both had 2 articles in the media. C4 Therapeutics' average media sentiment score of 0.89 beat Atai Beckley's score of 0.89 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TSHA or CCCC?

In the previous week, Taysha Gene Therapies had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Taysha Gene Therapies' score of 0.49 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CCCC or SION?

In the previous week, Sionna Therapeutics had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for Sionna Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Sionna Therapeutics' score of 0.29 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

C4 Therapeutics (CCCC) Competitors

$4.30 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.26 -0.04 (-1.05%)

As of 07/2/2026 07:50 PM Eastern

Compare

CCCC vs. GLUE, NUVB, ATAI, TSHA, and SION

Should you buy C4 Therapeutics stock or one of its competitors? MarketBeat compares C4 Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with C4 Therapeutics include Monte Rosa Therapeutics (GLUE), Nuvation Bio (NUVB), Atai Beckley (ATAI), Taysha Gene Therapies (TSHA), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry.

How does C4 Therapeutics compare to Monte Rosa Therapeutics?

Monte Rosa Therapeutics (NASDAQ:GLUE) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Monte Rosa Therapeutics has higher revenue and earnings than C4 Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	16.54	-$38.63M	-$1.48	N/A
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A

In the previous week, Monte Rosa Therapeutics had 7 more articles in the media than C4 Therapeutics. MarketBeat recorded 9 mentions for Monte Rosa Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Monte Rosa Therapeutics' score of 0.08 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, suggesting that its stock price is 190% more volatile than the broader market.

Monte Rosa Therapeutics currently has a consensus target price of $33.33, suggesting a potential upside of 37.68%. C4 Therapeutics has a consensus target price of $7.75, suggesting a potential upside of 80.23%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

C4 Therapeutics has a net margin of -297.76% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Summary

Monte Rosa Therapeutics beats C4 Therapeutics on 10 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Nuvation Bio currently has a consensus price target of $12.50, indicating a potential upside of 119.88%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 80.23%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Nuvation Bio has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market.

In the previous week, Nuvation Bio had 2 more articles in the media than C4 Therapeutics. MarketBeat recorded 4 mentions for Nuvation Bio and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Nuvation Bio's score of 0.63 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nuvation Bio has a net margin of -102.06% compared to C4 Therapeutics' net margin of -297.76%. Nuvation Bio's return on equity of -44.10% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-102.06%	-44.10%	-23.80%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

C4 Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$62.90M	31.47	-$204.63M	-$0.43	N/A
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A

Summary

Nuvation Bio beats C4 Therapeutics on 10 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Atai Beckley?

C4 Therapeutics (NASDAQ:CCCC) and Atai Beckley (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, C4 Therapeutics and C4 Therapeutics both had 2 articles in the media. C4 Therapeutics' average media sentiment score of 0.89 beat Atai Beckley's score of 0.89 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

C4 Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market.

C4 Therapeutics currently has a consensus target price of $7.75, suggesting a potential upside of 80.23%. Atai Beckley has a consensus target price of $16.00, suggesting a potential upside of 208.29%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

C4 Therapeutics has a net margin of -297.76% compared to Atai Beckley's net margin of -19,019.44%. C4 Therapeutics' return on equity of -50.68% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

C4 Therapeutics has higher revenue and earnings than Atai Beckley. C4 Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A
Atai Beckley	$4.09M	467.19	-$660.05M	-$2.23	N/A

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

C4 Therapeutics beats Atai Beckley on 9 of the 16 factors compared between the two stocks.

How does C4 Therapeutics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

In the previous week, Taysha Gene Therapies had 3 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Taysha Gene Therapies' score of 0.49 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Taysha Gene Therapies has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.9, indicating that its share price is 190% more volatile than the broader market.

Taysha Gene Therapies currently has a consensus price target of $12.62, indicating a potential upside of 93.19%. C4 Therapeutics has a consensus price target of $7.75, indicating a potential upside of 80.23%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, equities analysts plainly believe Taysha Gene Therapies is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

C4 Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	192.06	-$109M	-$0.38	N/A
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A

Taysha Gene Therapies has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Summary

C4 Therapeutics beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

How does C4 Therapeutics compare to Sionna Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Sionna Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -297.76%. Sionna Therapeutics' return on equity of -27.31% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Sionna Therapeutics	N/A	-27.31%	-25.88%

78.8% of C4 Therapeutics shares are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Sionna Therapeutics had 6 more articles in the media than C4 Therapeutics. MarketBeat recorded 8 mentions for Sionna Therapeutics and 2 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.89 beat Sionna Therapeutics' score of 0.29 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

C4 Therapeutics has a beta of 2.9, indicating that its stock price is 190% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 80.23%. Sionna Therapeutics has a consensus price target of $53.22, suggesting a potential upside of 20.99%. Given C4 Therapeutics' higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Sionna Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	13.23	-$104.99M	-$1.19	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Summary

C4 Therapeutics and Sionna Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get C4 Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CCCC vs. The Competition

Export

Metric	C4 Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$475.44M	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-3.61	21.61	28.02	24.70
Price / Sales	13.23	338.16	537.00	97.28
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.62	8.66	10.96	6.46
Net Income	-$104.99M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.94%	3.39%	2.12%	1.69%
1 Month Performance	11.69%	10.81%	5.25%	3.81%
1 Year Performance	188.59%	62.61%	33.29%	23.90%

C4 Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CCCC C4 Therapeutics	1.8401 of 5 stars	$4.30 flat	$7.75 +80.2%	+188.6%	$475.44M	$35.95M	N/A	150	News Coverage
GLUE Monte Rosa Therapeutics	1.9885 of 5 stars	$23.96 +0.3%	$33.33 +39.1%	+379.9%	$2.03B	$123.67M	N/A	90	News Coverage Analyst Forecast Insider Trade Gap Down
NUVB Nuvation Bio	4.0321 of 5 stars	$5.79 +3.1%	$12.50 +116.1%	+172.7%	$2.02B	$143.05M	N/A	60	Gap Down
ATAI Atai Beckley	3.5663 of 5 stars	$5.49 +2.3%	$16.00 +191.7%	+87.0%	$2.00B	$3.49M	N/A	80	News Coverage Gap Down
TSHA Taysha Gene Therapies	3.1774 of 5 stars	$6.92 +2.8%	$12.62 +82.3%	+172.1%	$1.98B	$9.77M	N/A	180	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CCCC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

C4 Therapeutics (CCCC) Competitors

CCCC vs. GLUE, NUVB, ATAI, TSHA, and SION

How does C4 Therapeutics compare to Monte Rosa Therapeutics?

Summary

How does C4 Therapeutics compare to Nuvation Bio?

Summary

How does C4 Therapeutics compare to Atai Beckley?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Summary

How does C4 Therapeutics compare to Sionna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

C4 Therapeutics (CCCC) Competitors

CCCC vs. GLUE, NUVB, ATAI, TSHA, and SION

How does C4 Therapeutics compare to Monte Rosa Therapeutics?

Which has better valuation and earnings, GLUE or CCCC?

Does the media favor GLUE or CCCC?

Which has more volatility and risk, GLUE or CCCC?

Do analysts prefer GLUE or CCCC?

Do insiders & institutionals hold more shares of GLUE or CCCC?

Is GLUE or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Nuvation Bio?

Do analysts rate NUVB or CCCC?

Which has more volatility & risk, NUVB or CCCC?

Does the media refer more to NUVB or CCCC?

Do institutionals & insiders have more ownership in NUVB or CCCC?

Is NUVB or CCCC more profitable?

Which has higher earnings and valuation, NUVB or CCCC?

Summary

How does C4 Therapeutics compare to Atai Beckley?

Does the media refer more to CCCC or ATAI?

Which has more risk and volatility, CCCC or ATAI?

Do analysts prefer CCCC or ATAI?

Is CCCC or ATAI more profitable?

Which has higher valuation and earnings, CCCC or ATAI?

Do insiders and institutionals hold more shares of CCCC or ATAI?

Summary

How does C4 Therapeutics compare to Taysha Gene Therapies?

Does the media favor TSHA or CCCC?

Do insiders and institutionals believe in TSHA or CCCC?

Which has more risk and volatility, TSHA or CCCC?

Do analysts prefer TSHA or CCCC?

Which has stronger valuation and earnings, TSHA or CCCC?

Is TSHA or CCCC more profitable?

Summary

How does C4 Therapeutics compare to Sionna Therapeutics?

Is CCCC or SION more profitable?

Do institutionals and insiders hold more shares of CCCC or SION?

Does the media prefer CCCC or SION?

Which has more risk & volatility, CCCC or SION?

Do analysts rate CCCC or SION?

Which has stronger earnings and valuation, CCCC or SION?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CCCC vs. The Competition

C4 Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools